Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | LAP3 | P28838 | 1/20 | 0.45 |
| ▸ | PNMT | P11086 | 4/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6277445 | 1.00 | HSP90AA1 (0.45) | HSP90AA1LAP3PNMTADRA2AMEN1 | |
| Hydrochloric Acid SCHEMBL8176659 | 0.98 | LAP3 (0.47) | HSP90AA1LAP3PNMTADRA2AMEN1 | |
| Hydrochloric Acid SCHEMBL8685041 | 0.91 | LAP3 (0.48) | LAP3MEN1KMT2AGRIN2B | |
| SCHEMBL6478814 | 0.90 | HSP90AA1 (0.47) | HSP90AA1PNMTADRA2AMEN1LMNA | |
| SCHEMBL30073945 | 0.90 | HSP90AA1 (0.47) | HSP90AA1PNMTADRA2AMEN1LMNA | |
| SCHEMBL2244560 | 0.87 | LAP3 (0.48) | HSP90AA1LAP3PNMTADRA2AMEN1 | |
| SCHEMBL4870044 | 0.81 | HSP90AA1 (0.44) | HSP90AA1PNMTADRA2AMEN1LMNA | |
| SCHEMBL6359153 | 0.81 | HSP90AA1 (0.44) | HSP90AA1PNMTADRA2AMEN1LMNA | |
| SCHEMBL4873492 | 0.81 | HSP90AA1 (0.44) | HSP90AA1PNMTADRA2AMEN1LMNA | |
| SCHEMBL6575270 | 0.81 | HSP90AA1 (0.44) | HSP90AA1PNMTADRA2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415756-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | Shionogi&Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-7378447-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7326731-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2005-09-08 | — | — | US | disclosed |
| EP-0923543-B1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-6083986-A | Potassium channel inhibitors | ICAGEN, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| WO-1999052857-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1999-10-21 | — | — | WO | disclosed |
| EP-0923543-A1 | POTASSIUM CHANNEL INHIBITORS | Icagen, Inc. (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998004521-A1 | POTASSIUM CHANNEL INHIBITORS | ICAGEN, INC. (US) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997006158-A1 | BICYCLIC AMIDINE DERIVATIVES USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015961-A1 | ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | HSP90AA1 2290/4885LAP3 313/4885PNMT 2827/4885 |
| US-20050197365-A1 | Diamino thiazoloindan derivatives and their use | RTN3, RTN4, DRD4 | HSP90AA1 4588/4885LAP3 1053/4885PNMT 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.